Comment: The quality of evidence is downgraded by study limitations (unclear allocation concealment and no blinding in half of the trials).
A Cochrane review [Abstract] 1 included 45 RCTs involving a total of 7 511 participants comparing the GnRH antagonist to the long protocol of GnRH agonist. There was no evidence of a statistically significant difference in live-birth rate in the antagonist group (odds ratio (OR) 0.86, 95% CI 0.69 to 1.08; 9 trials, n=1515). However, there was statistically significant reduction in incidence of ovarian hyperstimulation syndrome with antagonist protocol (RR 0.43, 95% CI 0.33 to 0.57; 29 trials).
Primary/Secondary Keywords